% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

  • uplatas uplatas Aug 23, 2013 4:59 PM Flag

    SLXP Xifaxan rifaximin vs SNTS Rifamycin SV MMX and RUCONEST SAN 300

    As per the SNTS
    Clinical activity in infectious diarrhea appears comparable to Xifaxan®

    SLXP makes per quarter $150.6 million x 4 = $600M yearly
    FDA approval hepatic encephalopathy
    Salix is also looking to develop an extended intestinal release (:EIR) version of rifaximin for Crohn’s disease. Patient enrolment in two phase III studies is expected to commence in the second half of the year.

    SNTS should be able to grab $15M per quarter as starter
    that would be another $60M / year on $350 + $50M = $400M
    and RUCONEST another $15M / Quarter that would give $450M / year with 0 growth and min sales

    Not included acute pancreatitis for Ruconest which has a huge market.

    SNTS has market cap of $1.6Billion market cap and should be atleast $5 Billion market after Rifamycin and Ruconest

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies